Thursday, April 29, 2021

Functional Dyspepsia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Functional Dyspepsia Market Analysis, Leading Companies, Emerging Drugs, and Epidemiology Forecast
Delveinsight Business Research LLP
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dyspepsia is a common symptom with an extensive differential diagnosis and heterogeneous pathophysiology. The majority of patients with symptoms of dyspepsia are eventually categorized as having functional (idiopathic, non-ulcer) dyspepsia (FD) means no obvious cause for the symptoms present. FD is one of the most common gastrointestinal disorders and imposes a social and economic burden worldwide.

Like other GI disorders, the treatment methods to FD depend on the severity of the disorder, which is determined by the intensity and constancy of the symptoms, the degree of psychosocial difficulties, and the frequency of need for health care assistance.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights

The Functional Dyspepsia market report also covers emerging drugs, current treatment practices, Functional Dyspepsia market share of the individual therapies, current and forecasted Functional Dyspepsia Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Functional Dyspepsia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Functional Dyspepsia Market

Functional Dyspepsia Market Key Facts

  • According to the article by Madisch et al. (2018), FD is one of the more common functional disorders, with a prevalence of 10–20%. It affects the gastrointestinal tract.

  • According to the article by Longstreth et al. (2019), approximately 25% of patients with dyspepsia have an underlying organic cause, and nearly 75% of patients have functional (idiopathic or non-ulcer) dyspepsia with no underlying cause on diagnostic evaluation.
  • As per Talley et al. (2015), of patients with FD, approximately 38% are classified with postprandial distress syndrome, 27% are classified with epigastric pain syndrome, and 35% meet the criteria for both.

Key Benefits of Functional Dyspepsia Market Report

  • Functional Dyspepsia market report provides an in-depth analysis of Functional Dyspepsia Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets, i.e. EU5 (Germany, Italy, Spain, France, and the UK), Japan, and the United States.

  • The Functional Dyspepsia market report will help in developing business strategies by understanding the Functional Dyspepsia Market trends & developments, key players, and future market competition that will shape and drive the Functional Dyspepsia market in the upcoming years.

  • The Functional Dyspepsia market report covers Functional Dyspepsia current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Functional Dyspepsia market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Functional Dyspepsia Market

Functional Dyspepsia Market Size is anticipated to increase during the study period owing to the increase in geriatric population and changing dietary habits in the 7MM which increase the cases of FD.

The Functional Dyspepsia market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Functional Dyspepsia market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology. 

The report gives a thorough detail of the Functional Dyspepsia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Functional Dyspepsia Epidemiology

The Functional Dyspepsia epidemiology section covers insights about the historical and current Functional Dyspepsia patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Functional Dyspepsia Drugs Uptake and Key Market Players

The Functional Dyspepsia Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Functional Dyspepsia market or expected to get launched in the market during the study period. The analysis covers Functional Dyspepsia market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Limited late-stage pipeline activities have been observed in FD, besides, most of the trials are either completed or suspended, or terminated. Still, some of the key players are active in the Functional Dyspepsia therapeutics domain.

Functional Dyspepsia Companies:
Zeria Pharmaceutical
RaQualia Pharma
Jiangxi Qingfeng Pharmaceutical
And many others.

Functional Dyspepsia Therapies covered in the report include:
ISOT-101
RQ-00000010
Aolanti Weipang Tablets
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Functional Dyspepsia Competitive Intelligence Analysis

4. Functional Dyspepsia Market Overview at a Glance

5. Functional Dyspepsia Disease Background and Overview

6. Functional Dyspepsia Patient Journey

7. Functional Dyspepsia Epidemiology and Patient Population

8. Functional Dyspepsia Treatment Algorithm, Current Treatment, and Medical Practices

9. Functional Dyspepsia Unmet Needs

10. Key Endpoints of Functional Dyspepsia Treatment

11. Functional Dyspepsia Marketed Products

12. Functional Dyspepsia Emerging Therapies

13. Functional Dyspepsia Seven Major Market Analysis

14. Attribute Analysis

15. Functional Dyspepsia Market Outlook (7 major markets)

16. Functional Dyspepsia Access and Reimbursement Overview

17. KOL Views on the Functional Dyspepsia Market.

18. Functional Dyspepsia Market Drivers

19. Functional Dyspepsia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/functional-dyspepsia-market-insights

Latest Reports By DelveInsight:-
Lamellar Ichthyosis Market Size and Share Analysis
DelveInsight' s “Lamellar Ichthyosis Market Insights, Epidemiology and Market Forecast - 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology and the Lamellar Ichthyosis market size, share, trends, and forecast for the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/